178 related articles for article (PubMed ID: 35853850)
21. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
Hermel DJ; Cheng B; Bhangoo MS; Burian C; Waalen J; Saven A
Ann Hematol; 2022 May; 101(5):1089-1096. PubMed ID: 35218397
[TBL] [Abstract][Full Text] [Related]
23. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
24. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia.
Dearden CE; Else M; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():21-4. PubMed ID: 21599603
[TBL] [Abstract][Full Text] [Related]
25. [Hairy cell leukemia treated with cladribine].
Ghanima W; Heldal D; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2002 Apr; 122(11):1094-7. PubMed ID: 12043051
[TBL] [Abstract][Full Text] [Related]
26. Treatment Outcomes Of Patients With Hairy Cell Leukaemia; A 16-Year Experience At A Tertiary Care Center In Pakistan.
Yousaf M; Khan MA; Iftikhar R; Chaudary QU; Shahbaz N; Ahmad U; Javed H
J Ayub Med Coll Abbottabad; 2022; 34(4):797-801. PubMed ID: 36566402
[TBL] [Abstract][Full Text] [Related]
27. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
Zinzani PL; Tani M; Marchi E; Stefoni V; Alinari L; Musuraca G; Gabriele A; Pileri S; Baccarani M
Haematologica; 2004 Mar; 89(3):309-13. PubMed ID: 15020269
[TBL] [Abstract][Full Text] [Related]
29. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Ravandi F; O'Brien S; Jorgensen J; Pierce S; Faderl S; Ferrajoli A; Koller C; Challagundla P; York S; Brandt M; Luthra R; Burger J; Thomas D; Keating M; Kantarjian H
Blood; 2011 Oct; 118(14):3818-23. PubMed ID: 21821712
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of hairy cell leukemia with cladribine].
Aurer I; Mitrović Z; Kovacević-Metelko J; Radman I; Basić-Kinda S; Gjadrov-Kuvezdić K; Jakić-Razumović J; Dubravcić K; Ries S; Nola M; Zupancic-Salek S; Labar B
Lijec Vjesn; 2007; 129(3-4):80-3. PubMed ID: 17557550
[TBL] [Abstract][Full Text] [Related]
31. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.
Else M; Ruchlemer R; Osuji N; Del Giudice I; Matutes E; Woodman A; Wotherspoon A; Swansbury J; Dearden C; Catovsky D
Cancer; 2005 Dec; 104(11):2442-8. PubMed ID: 16245328
[TBL] [Abstract][Full Text] [Related]
32. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.
Tallman MS; Hakimian D; Rademaker AW; Zanzig C; Wollins E; Rose E; Peterson LC
Blood; 1996 Sep; 88(6):1954-9. PubMed ID: 8822913
[TBL] [Abstract][Full Text] [Related]
33. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Haferlach T; Heinemann V
Leukemia; 2004 Sep; 18(9):1476-81. PubMed ID: 15229616
[TBL] [Abstract][Full Text] [Related]
34. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Chadha P; Rademaker AW; Mendiratta P; Kim B; Evanchuk DM; Hakimian D; Peterson LC; Tallman MS
Blood; 2005 Jul; 106(1):241-6. PubMed ID: 15761021
[TBL] [Abstract][Full Text] [Related]
35. Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.
Inbar M; Herishanu Y; Goldschmidt N; Bairey O; Yuklea M; Shvidel L; Fineman R; Aviv A; Ruchlemer R; Braester A; Najib D; Rouvio O; Shaulov A; Greenbaum U; Polliack A; Tadmor T
Anticancer Res; 2018 Nov; 38(11):6423-6429. PubMed ID: 30396967
[TBL] [Abstract][Full Text] [Related]
36. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy.
Mercieca J; Matutes E; Emmett E; Coles H; Catovsky D
Br J Haematol; 1996 May; 93(2):409-11. PubMed ID: 8639440
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Zinzani PL; Magagnoli M; Bendandi M; Tani M; Stefoni V; Cellini C; Poggi S; Piccioli M; Pileri S; Tura S
Haematologica; 2000 Sep; 85(9):922-5. PubMed ID: 10980629
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
39. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia.
Nieva J; Bethel K; Saven A
Blood; 2003 Aug; 102(3):810-3. PubMed ID: 12663446
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hairy cell leukemia: long-term results in a developing country.
Ruiz-Delgado GJ; Tarín-Arzaga LC; Alarcón-Urdaneta C; Calderón-García J; Gómez-Almaguer D; Ruiz-Argüelles GJ
Hematology; 2012 May; 17(3):140-3. PubMed ID: 22664112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
